Cyclosporine Drugs Market Report 2026

Cyclosporine Drugs Market Overview

• Cyclosporine Drugs market size has reached to $1.73 billion in 2025 • Expected to grow to $2.32 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Surge in Organ Transplantation Driving The Growth Of The Market Due To Increasing Demand For Organ Replacements • Market Trend: Advancements In Ophthalmic Drug Delivery Driving Innovation In Dry Eye Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cyclosporine Drugs Market?

Cyclosporine drugs are a class of immunosuppressive medications primarily used to prevent the body from rejecting transplanted organs and to treat certain autoimmune disorders. These drugs function by inhibiting the activity of T-lymphocytes, a type of white blood cell involved in the immune response, thereby reducing inflammation and immune system overactivity. The main types of cyclosporine drugs include oral and parenteral. Oral cyclosporine drugs are immunosuppressive medications taken by mouth to inhibit immune system activity. It is available in various formulations such as capsules, oral solutions, injectable forms, and topical preparations, and applied for organ transplantation, autoimmune disorders, ophthalmic disorders, and dermatological disorders by different end-users, including hospitals, specialty clinics, homecare settings, and pharmaceutical retail.

What Is The Cyclosporine Drugs Market Growth Forecast?

The cyclosporine drugs market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growth in transplant patient population, expansion of ophthalmic treatment indications, development of improved drug delivery systems, increasing demand for personalized immunosuppressive therapy, advancements in formulation technologies. Major trends in the forecast period include growing use in organ transplant immunosuppression, increasing application in autoimmune disorders, rising demand for modified release formulations, expansion of ophthalmic cyclosporine products, increased focus on dose optimization and safety.

Global Cyclosporine Drugs Market Segmentation

1) By Type: Oral, Parenteral 2) By Drug Formulation: Capsules, Oral Solutions, Injectable Forms, Topical Preparations 3) By Application: Organ Transplantation, Autoimmune Disorders, Ophthalmic Disorders, Dermatological Disorders 4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Pharmaceutical Retail Subsegments: 1) By Oral: Capsules, Tablets, Oral Solution 2) By Parenteral: Intravenous Injection, Intravenous Infusion

What Is The Driver Of The Cyclosporine Drugs Market?

The increasing organ transplantation demand is anticipated to propel the growth of the cyclosporine drugs market going forward. Organ transplantation is a medical procedure where a damaged or failing organ in a person's body is replaced with a healthy organ from another person. Organ transplantation is rising due to the increasing prevalence of end-stage organ diseases, as advancements in medical diagnostics and treatment have extended patient lifespans, leading to a greater number of individuals living long enough to require organ replacement. Cyclosporine drugs are required for organ transplantation as they suppress the immune system's natural response to reject foreign tissues, thereby helping to prevent the transplanted organ from being attacked and damaged by the recipient’s immune cells. For instance, in January 2025, according to preliminary data published by the Organ Procurement and Transplantation Network (OPTN), a US-based government health system managed by the Health Resources and Services Administration, the United States performed 48,149 organ transplants in 2024, representing a 3.3% increase from the transplants performed in 2023. Therefore, the increasing organ transplantation demand is driving the growth of the cyclosporine drugs industry.

Key Players In The Global Cyclosporine Drugs Market

Major companies operating in the cyclosporine drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Astellas Pharma Inc., Apotex Inc., Dr. Reddy’s Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Santen Pharmaceutical Co. Ltd., Biocon Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Concord Biotech Limited, CKD Bio Corporation, ChemWerth Inc., Strides Pharma Science Limited, Fishfa Biogenics.

Global Cyclosporine Drugs Market Trends and Insights

Major companies operating in the cyclosporine drugs market are focusing on developing advanced solutions, such as ophthalmic medications, to provide targeted treatment directly to the eyes. Ophthalmic medications are pharmaceutical products specifically formulated for the treatment of eye conditions, including infections, inflammation, and dry eye, often available in the form of drops, ointments, or gels. For instance, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for VEVYE, the first water-free and preservative-free 0.1% cyclosporine ophthalmic solution. VEVYE, developed with Novaliq’s proprietary EyeSol technology, introduces an innovative solution for treating dry eye disease, showing significant effectiveness within four weeks. Its unique water-free formulation improves drug stability and enhances patient comfort while minimizing irritation. This approval marks a significant advancement in ophthalmic drug delivery, offering more precise targeting of inflammation.

What Are Latest Mergers And Acquisitions In The Cyclosporine Drugs Market?

In October 2024, Novaliq GmbH, a Germany-based manufacturer of cyclosporine drugs, partnered with Laboratoires Théa to market ciclosporin eye drop solution in Europe and a few Middle Eastern and North African nations. The partnership with Novaliq underscores a commitment to providing innovative treatments for patients. The upcoming launch of Vevizye will enhance the portfolio of non-preserved treatments for dry eye, a condition that significantly affects the quality of life for many individuals. Laboratoires Théa is a France-based pharmaceutical company.

Regional Insights

North America was the largest region in the cyclosporine drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cyclosporine Drugs Market?

The cyclosporine drugs market consists of sales of therapeutic drug monitoring kits, supportive care medications and cyclosporine active pharmaceutical ingredient. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cyclosporine Drugs Market Report 2026?

The cyclosporine drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.